Work

Supplementary Tables 1-3 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Year: 2023

Type: supplementary-materials

Abstract: Table S1: Inclusion and exclusion criteria for study eligibility; Table S2: PCR primer and probe sequences; Table S3: Patient and tumor characteristics.

DOI: 10.1158/1078-0432.22468263

Authors: Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362404869

Cites:

Cited by:

Related to: 10